TG Therapeutics, Inc. (NASDAQ:TGTX) to Post FY2025 Earnings of $0.72 Per Share, B. Riley Forecasts

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued on Wednesday, May 1st. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of $0.72 for the year, down from their prior estimate of $0.78. B. Riley has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.10) per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.46 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The business’s revenue for the quarter was up 713.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.28) EPS.

A number of other brokerages have also recently issued reports on TGTX. StockNews.com cut TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. LADENBURG THALM/SH SH upped their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright lifted their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.83.

TG Therapeutics Stock Performance

TGTX opened at $16.19 on Friday. The business’s 50-day simple moving average is $15.19 and its 200 day simple moving average is $14.34. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $35.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The firm has a market capitalization of $2.50 billion, a PE ratio of 71.30 and a beta of 2.33.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund increased its position in TG Therapeutics by 1.2% during the fourth quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock worth $960,000 after acquiring an additional 663 shares during the period. Kestra Advisory Services LLC grew its position in TG Therapeutics by 8.2% during the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,240 shares in the last quarter. Principal Financial Group Inc. increased its stake in TG Therapeutics by 3.9% during the 1st quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after acquiring an additional 1,322 shares during the period. Arizona State Retirement System raised its holdings in TG Therapeutics by 3.5% in the 3rd quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company’s stock valued at $338,000 after acquiring an additional 1,356 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in shares of TG Therapeutics by 2.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock valued at $1,081,000 after acquiring an additional 1,500 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.